KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
9.00
+0.04 (0.45%)
Nov 21, 2024, 1:38 PM EST - Market open
KalVista Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
150
Market Cap
388.94M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DocGo | 694.97M |
Revance Therapeutics | 256.95M |
Sonida Senior Living | 253.20M |
Canopy Growth | 207.63M |
Rigel Pharmaceuticals | 157.37M |
Aquestive Therapeutics | 58.90M |
Sangamo Therapeutics | 52.29M |
Prime Medicine | 800.00K |
KALV News
- 9 days ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire
- 16 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - Business Wire
- 17 days ago - KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust - Business Wire
- 24 days ago - KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - Business Wire
- 6 weeks ago - KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum - Business Wire
- 7 weeks ago - KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema - Business Wire